Semaglutide promoted T cells to be able to respond more effectively to cancer.[ref] More research is needed here, of course
Citing limitations in the study, Novo Nordisk, which makes the drugs included in the claims analysis, said in a statement reported by Reuters that it does not believe these data are sufficient to draw conclusions about overall patient adherence and persistence to various GLP-1 medicines, including our treatments. Nonetheless, the problem of lack of patient persistence on GLP-1s under real-world conditions, examined and published by a growing number of sources, isnt going away
Companies are pouring resources into anything that might become the next semaglutide. The combination of licensing deals, strategic partnerships, and IPOs underscores that investment in new obesity drugs is red-hot across the industry
You want to permanently change your injection day
Small molecules like nicotine can move through skin, but larger ones usually cannot
Transcription factor STAT3 as a novel molecular target for cancer prevention